As the first small-molecule drug targeting RNA gains momentum, the ability to design small molecules capable of interacting with and modulating RNA is opening as a new avenue to target challenging disease pathways that have previously been considered undruggable.

The 5th RNA-Targeted Drug Discovery Summit will return once again this December, to reunite the largest community of thought leaders and experts in biology, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.

Join the leading RNA small molecule forum alongside 150+ biopharmaceutical Directors, VPs and C-Level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field.